文献速递心律失常冠心病

EPIC-CAD 试验:房颤合并稳定型冠心病患者中超说明书减量艾多沙班的影响

Off-label underdosing of edoxaban antithrombotic therapy for patients with atrial fibrillation and stable coronary artery disease: findings from the EPIC-CAD trial.
PubMed 文献 · Heart · 2026-03-12

EPIC-CAD 试验纳入 1040 例房颤合并稳定型冠心病患者,其中 694 例无减量指征者中 121 例(17.4%)接受超说明书减量艾多沙班(30 mg 每日一次)。12 个月时标准剂量组与减量组主要终点发生率相似(10.5% vs 9.2%,校正 HR 0.77,95%CI 0.39–1.54)。无论是否减量,艾多沙班单药治疗较双联抗栓治疗主要净临床结局和出血风险更低,但分析效能不足且置信区间宽,结果不能视为临床指导。

要点

  • 无减量指征的房颤合并稳定型冠心病患者中超说明书减量艾多沙班占17.4%。
  • 减量与标准剂量艾多沙班12个月主要终点发生率无显著差异。
  • 无论是否减量,艾多沙班单药较双联抗栓主要净临床结局和出血风险更低。

核心结论

  • 在房颤合并稳定型冠心病患者中,超说明书减量艾多沙班与标准剂量相比主要终点发生率无显著差异。
  • 艾多沙班单药治疗较双联抗栓治疗的获益不受超说明书减量影响。
  • 因分析效能不足且置信区间宽,结果不能视为临床指导。

研究设计与样本

  • EPIC-CAD 试验将房颤合并稳定型冠心病患者随机分配至艾多沙班单药治疗或双联抗栓治疗(艾多沙班联合单一抗血小板药)。
  • 共纳入1040例随机患者,其中694例(66.7%)无减量指征者纳入本分析,121例(17.4%)接受超说明书减量艾多沙班(30 mg每日一次)。
  • 主要终点为12个月时死亡、心肌梗死、卒中、系统性栓塞、非计划血运重建及大出血或临床相关非大出血的复合终点。

主要发现

  • 12个月时标准剂量组与减量组主要终点发生率分别为10.5%和9.2%(校正HR 0.77,95%CI 0.39–1.54)。
  • 主要缺血事件发生率分别为1.4%和1.7%(HR 1.14,95%CI 0.22–5.91)。
  • 大出血或临床相关非大出血发生率分别为9.0%和8.4%(HR 0.87,95%CI 0.42–1.78)。

关键数值与推荐

  • 超说明书减量定义为无标准减量指征情况下使用低剂量艾多沙班(30 mg每日一次)。

临床怎么用

  • 对于无减量指征的房颤合并稳定型冠心病患者,超说明书减量艾多沙班未显示显著临床获益差异,但因效能不足不应据此常规减量。
  • 艾多沙班单药治疗较双联抗栓治疗可能降低主要净临床结局和出血风险,且该获益不受超说明书减量影响。

局限性

  • 分析效能不足且置信区间宽,结果不能视为临床指导。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The impact of off-label underdosing of direct oral anticoagulants (DOACs) on clinical outcomes in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) remains unclear. METHODS: The EPIC-CAD trial (Edoxaban vs Edoxaban with antiPlatelet agent In patients with atrial fibrillation and Chronic stable Coronary Artery Disease) randomised patients with AF and stable CAD to receive either edoxaban monotherapy or dual antithrombotic therapy (edoxaban plus single antiplatelet agent). Off-label underdosing was defined as low-dose edoxaban (30 mg once daily) without standard criteria for dose reduction. The primary outcome was a composite of death, myocardial infarction, stroke, systemic embolism, unplanned revascularisation and major or clinically relevant non-major bleeding at 12 months. RESULTS: Among the 1040 randomised patients, 694 patients (66.7%) without dose-reduction criteria were included; of whom, 121 patients (17.4%) received edoxaban underdosing. At 12 months, the incidence of primary outcome was similar between standard-dose and under-dose edoxaban groups (10.5% vs 9.2%, adjusted HR 0.77, 95% CI 0.39 to 1.54). There was no significant difference in major ischaemic events (1.4% vs 1.7%, HR 1.14, 95% CI 0.22 to 5.91) and major or clinically relevant non-major bleeding (9.0% vs 8.4%, HR 0.87, 95% CI 0.42 to 1.78). Regardless of edoxaban underdosing, edoxaban monotherapy was associated with lower risk of primary net-clinical outcomes and bleeding compared with dual antithrombotic therapy. CONCLUSIONS: In patients with AF and stable CAD, there was no significant difference in the rate of primary outcome between off-label underdose and standard-dose edoxaban. The benefit of edoxaban monotherapy over dual antithrombotic therapy was consistent regardless of edoxaban underdosing. However, given the analyses were underpowered and the CI was wide, the results cannot be considered clinically directive. TRIAL REGISTRATION NUMBER: URL: https://www. CLINICALTRIALS: gov; unique identifiers: NCT03718559.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Cho, Kang, Lee, et al. Off-label underdosing of edoxaban antithrombotic therapy for patients with atrial fibrillation and stable coronary artery disease: findings from the EPIC-CAD trial. Heart. 2026. PMID: 40930594. doi:10.1136/heartjnl-2025-326646

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。